Nkarta NKX101 achieves 67% CR/CRi in AML Phase 1 with modified lymphodepletion

Nkarta, Inc.

In Flu/Ara-C cohort (n=6), NKX101 showed 67% CR/CRi rate (4/6) and 50% CR rate (3/6); 2 CRs MRD-negative.
In Flu/Cy highest-dose cohort (n=18), CR/CRi rate was 22% (4/18) and CR rate 17% (3/18).
NKX101 well tolerated; no dose-limiting toxicities, limited CRS/ICANS/GvHD across all doses.
Expansion cohort with Flu/Ara-C to enroll 12-20 more patients; clinical update expected 1H 2024.
Patients heavily pre-treated (median 2 prior lines, 90%+ prior venetoclax); majority poor-risk disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.